Director of Hematology - 2361
What if you could repair broken genes? That is the question we ask ourselves at Editas Medicine. We’re focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for many diseases. We’re looking for talented, dedicated, passionate people to join our team and help us pioneer this field and do big, bold things that have never been achieved before. Are you full of hope, possibilities, and a belief that, working together, we can truly revolutionize the development of medicines to help patients around the world? If the answer is yes, then Editas Medicine is the place for you.
Editas Medicine is seeking a highly motivated and dynamic leader to lead the development of genome editing medicine to treat hematological diseases. This individual will lead a team of scientists to perform research ranging from early discovery to supporting regulatory filings. The individual will actively participate in program teams and collaborate effectively across functions; contribute to advancing Editas’ EDIT-301 program for beta hemoglobinopathies to commercialization; and leading effort in developing milder conditioning regimen and in vivo HSC editing. The successful candidate shall demonstrate a proven track record in development experience with biologics, nucleic acid-based, or gene therapy products through IND/BLA and possess a solid understanding of FDA/EMA guidelines. This individual will be collaborative, goal-oriented, and timeline sensitive while maintaining high quality output.
- Manage a diverse team of scientists to perform research supporting development of HSC-based therapies from early discovery to regulatory filing.
- Lead the discovery effort to identify milder conditioning regimen to improve patient experience and access to EDIT-301
- Lead the discovery effort for in vivo editing of HSCs to treat hematological diseases.
- Develop project strategy, understand timeline and deliverables, plan, and coordinate project work with functional stakeholders.
- Contribute to building the product strategy for EDIT-301 including life-cycle management and path to commercialization.
- Effectively manage CROs, academic collaborators, and KOLs.
- Establish SOPs, write prospective protocols, author study reports and regulatory documents, assist patent filing, and contribute to business development activities.
- Serve as a technical and scientific resource for junior staff.
- Skillfully manage diverse team interactions.
- Consistently role model Editas values and behaviors as a people manager to positively influence our culture and engagement.
- Ph.D in hematology or related field of study with minimum of ten years of working experience, including strong track record of hands-on experience in development of gene and cell therapy in pharmaceutical and/or biotechnology industry.
- Solid understanding of hematopoietic stem cell biology is required.
- Working experience with lipid nano particles for targeted delivery in vivo is highly desirable.
- Familiarity with FDA and EMA guidance for cell and gene therapy and experience with IND-filing.
- A minimum of five years managerial experience that demonstrates effective leadership across a cross-functional setting.
- Ability to think critically, synthesize and extract simple principles from complex datasets, communicate effectively across broad spectrum of audience both internal and external to Editas, excellent written skills.
- Ability to conduct high-quality research and execute research plans in a timely and organized manner.
- Must be able to adjust quickly to changing priorities.
Editas provides a comprehensive array of benefits to all employees, including a Blue Cross Blue Shield PPO Medical Plan, a company-funded Health Savings Account, Dental and Vision Insurance, Life and Disability Insurance, Dependent Care Account, Tuition Reimbursement, 401(k) plan with company match, Employee Stock Purchase Plan, Employee Assistance Plan, Wellness Programs, and a flexible Paid Time Off policy.
Something looks off?